Old and emerging therapies for childhood interstitial lung disease (chILD): a systematic review [0.03%]
儿童间质性肺病（chILD）的旧有和新兴疗法：系统综述
Valentina Tonazzo,Raimondo Junior Castaldo,Stefania Zanconato et al.
Valentina Tonazzo et al.
Childhood interstitial lung disease (chILD) is a heterogeneous group of rare lung diseases that comprises more than 200 entities. The diagnostic process for chILD might require multiple investigations, which often include a combination of c...
The impact of elexacaftor-tezacaftor-ivacaftor on cardiometabolic risk factors: a systematic review [0.03%]
Elexacaftor-tezacaftor-ivacaftor对心代谢风险因素的影响：系统性综述
Heather Girouard,Farah Jaber,Josh Gharib et al.
Heather Girouard et al.
Elexacaftor-tezacaftor-ivacaftor (ETI) is a highly effective modulator therapy associated with significant improvements in respiratory function and quality of life among people living with cystic fibrosis (CF). However, ETI has also been sh...
Physical inactivity in chronic airways disease: an important candidate in the treatable traits paradigm [0.03%]
慢性呼吸道疾病中的身体不活动性：可治疗特征范式中的重要候选因素
Benjamin Griffiths,Reem Alajmi,Ian J Clifton et al.
Benjamin Griffiths et al.
Background: Physical inactivity is a common and potentially modifiable trait in individuals with chronic airways disease, yet disease-specific physical activity profiles and clinical determinants remain poorly defined. ...
Bronchiectasis in children: a systematic review of cytokine profile, immune cell phenotypes and microbiota in bronchoalveolar lavage fluid [0.03%]
儿童支气管扩张的系统评价：支气管肺泡灌洗液细胞因子谱、免疫细胞表型及微生物群的研究
Christian Magnus Kragh Thomsen,Simon Kromann-Thomsen,Signe Thim et al.
Christian Magnus Kragh Thomsen et al.
Background: Paediatric noncystic fibrosis bronchiectasis (NCFB) is a chronic respiratory condition characterised by airway infection, chronic inflammation, mucociliary dysfunction and structural lung damage. Emerging evid...
Assessment and management of post-COVID-19 pulmonary complications: a rapid review [0.03%]
新型冠状肺炎后肺损伤的评估与管理：快速综述研究
Wade Michaelchuk,Lesley J J Soril,Dacia Chiarieri-Hirsch et al.
Wade Michaelchuk et al.
The rising global prevalence of post-COVID-19 condition (PCC) underscores the substantial and ongoing burden faced by individuals following severe acute respiratory syndrome coronavirus 2 infection. The volume of emerging evidence regarding...
Marc Peters-Golden,Sean M Fortier
Marc Peters-Golden
The human and economic impact of idiopathic pulmonary fibrosis and other interstitial lung diseases is enormous, and available therapies are of limited utility. A decade after the introduction of the first antifibrotic agents, two new agent...
Management of pulmonary arterial hypertension in systemic sclerosis: from classical treatments to new horizons [0.03%]
系统性硬化症肺动脉高压的治疗：从传统疗法到新视野
Annalisa Villa,Sébastien Sanges,Vincent Sobanski et al.
Annalisa Villa et al.
Pulmonary arterial hypertension (PAH) is a severe disease characterised by a progressive thickening and obliteration of pulmonary vessels, resulting in increased vascular resistance, elevated pulmonary artery pressures, and right heart fail...
Prince Ntiamoah,Felix Wireko,Ajay Wagh et al.
Prince Ntiamoah et al.
The bronchoscopic approach to diagnosing sarcoidosis has evolved significantly with the advent of advanced endoscopic and imaging-guided modalities. Bronchoscopy remains the cornerstone for both histological confirmation and therapeutic int...
Present and future of cytoreductive surgery and hyperthermic intrathoracic chemotherapy for pleural metastases: a narrative review [0.03%]
胸膜转移癌细胞减灭术和热灌注化疗现状及未来展望：综述
Amro Hajja,Miral Atout,Rasoul Turko et al.
Amro Hajja et al.
Background: Pleural malignancies pose a significant clinical challenge due to their poor prognosis and limited treatment options. Hyperthermic intrathoracic chemotherapy (HITHOC) is an emerging modality that has shown pro...
Pulmonary diffusing capacity for nitric oxide in disease: a scoping review [0.03%]
疾病状态下的肺一氧化氮弥散能力：系统评价
Thomas Radtke,Hà Pham-Ngoc,Thong Hua-Huy et al.
Thomas Radtke et al.
Objective: This scoping review aims to map the available studies on single-breath pulmonary diffusing capacity for nitric oxide (D LNO) in various clinical diseases and identify gaps for future research. ...